Pharmacokinetics of verapamil and its metabolite norverapamil in rats with hyperlipidaemia induced by poloxamer 407

References

• Ames RP. (1991). Hyperlipidemia in hypertension: causes and prevention. Am Heart J 122:1219–1224.
   PubMed Web of Science ®Google Scholar
• Boudinot FD, Jusko WJ. (1984). Fluid shifts and other factors affecting plasma protein binding of prednisolone by equilibrium dialysis. J Pharm Sci 73:774–780.
   PubMed Web of Science ®Google Scholar
• Bradford MM. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254.
   PubMed Web of Science ®Google Scholar
• Busse D, Cosme J, Beaune P, Kroemer HK, Eichelbaum M. (1995). Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol 353:116–121.
   PubMed Web of Science ®Google Scholar
• Chen M, Xu D, Hu XL, Wang H. (2008). Effects of liver fibrosis on verapamil pharmacokinetics in rats. Clin Exp Pharmacol Physiol 35:287–294.
   PubMed Web of Science ®Google Scholar
• Chen GM, Hu N, Liu L, Xie SS, Wang P, Li J, Xie L, Wang GJ, Liu XD. (2011). Pharmacokinetics of verapamil in diabetic rats induced by combination of high-fat diet and streptozotocin injection. Xenobiotica 41:494–500.
   PubMed Web of Science ®Google Scholar
• Chiou WL. (1978). Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level–time curve. J Pharmacokinet Biopharm 6:539–546.
   PubMedGoogle Scholar
• Dadashzadeh S, Javadian B, Sadeghian S. (2006). The effect of gender on the pharmacokinetics of verapamil and norverapamil in human. Biopharm Drug Dispos 27:329–334.
   PubMed Web of Science ®Google Scholar
• Das Gupta V. (1985). Quantitation and stability of verapamil hydrochloride using high-performance liquid chromatography. Drug Dev Ind Pharm 11:1497–1506.
   Web of Science ®Google Scholar
• Duggleby RG. (1995). Analysis of enzyme progress curves by nonlinear regression. Meth Enzymol 249:61–90.
   PubMed Web of Science ®Google Scholar
• Echizen H, Brecht T, Niedergesäss S, Vogelgesang B, Eichelbaum M. (1985a). The effect of dextro-, levo-, and racemic verapamil on atrioventricular conduction in humans. Am Heart J 109:210–217.
   PubMed Web of Science ®Google Scholar
• Echizen H, Vogelgesang B, Eichelbaum M. (1985b). Effects of d,l-verapamil on atrioventricular conduction in relation to its stereoselective first-pass metabolism. Clin Pharmacol Ther 38:71–76.
   PubMed Web of Science ®Google Scholar
• Echizen H, Manz M, Eichelbaum M. (1988). Electrophysiologic effects of dextro- and levo-verapamil on sinus node and AV node function in humans. J Cardiovasc Pharmacol 12:543–546.
   PubMed Web of Science ®Google Scholar
• Eliot LA, Jamali F. (1999). Pharmacokinetics and pharmacodynamics of nifedipine in untreated and atorvastatin-treated hyperlipidemic rats. J Pharmacol Exp Ther 291:188–193.
   PubMed Web of Science ®Google Scholar
• Eliot LA, Foster RT, Jamali F. (1999). Effects of hyperlipidemia on the pharmacokinetics of nifedipine in the rat. Pharm Res 16:309–313.
   PubMed Web of Science ®Google Scholar
• Fromm MF, Busse D, Kroemer HK, Eichelbaum M. (1996). Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 24:796–801.
   PubMed Web of Science ®Google Scholar
• Fuhr U, Müller-Peltzer H, Kern R, Lopez-Rojas P, Jünemann M, Harder S, Staib AH. (2002). Effects of grapefruit juice and smoking on verapamil concentrations in steady state. Eur J Clin Pharmacol 58:45–53.
   PubMed Web of Science ®Google Scholar
• Gensini GF, Comeglio M, Colella A. (1998). Classical risk factors and emerging elements in the risk profile for coronary artery disease. Eur Heart J 19 Suppl A:A53–A61.
   Google Scholar
• Gibaldi M, Perrier D eds (1982). Pharmacokinetics, 2nd ed. New York: Marcel-Dekker.
   Google Scholar
• Hanada K, Ikemi Y, Kukita K, Mihara K, Ogata H. (2008). Stereoselective first-pass metabolism of verapamil in the small intestine and liver in rats. Drug Metab Dispos 36:2037–2042.
   PubMed Web of Science ®Google Scholar
• Hoffman DJ, Seifert T, Borre A, Nellans HN. (1995). Method to estimate the rate and extent of intestinal absorption in conscious rats using an absorption probe and portal blood sampling. Pharm Res 12:889–894.
   PubMed Web of Science ®Google Scholar
• Hu N, Xie S, Liu L, Wang X, Pan X, Chen G, Zhang L, Liu H, Liu X, Liu X, Xie L, Wang G. (2011). Opposite effect of diabetes mellitus induced by streptozotocin on oral and intravenous pharmacokinetics of verapamil in rats. Drug Metab Dispos 39:419–425.
   PubMed Web of Science ®Google Scholar
• Johnson BM, Charman WN, Porter CJ. (2003). Application of compartmental modeling to an examination of in vitro intestinal permeability data: assessing the impact of tissue uptake, P-glycoprotein, and CYP3A. Drug Metab Dispos 31:1151–1160.
   PubMed Web of Science ®Google Scholar
• Johnson JA, Akers WS. (1995). Influence of metabolites on protein binding of verapamil enantiomers. Br J Clin Pharmacol 39:536–538.
   PubMedGoogle Scholar
• Johnston TP, Palmer WK. (1993). Mechanism of poloxamer 407-induced hypertriglyceridemia in the rat. Biochem Pharmacol 46:1037–1042.
   PubMed Web of Science ®Google Scholar
• Kang HE, Jung HY, Cho YK, Kim SH, Sohn SI, Baek SR, Lee MG. (2009). Pharmacokinetics of liquiritigenin in mice, rats, rabbits, and dogs, and animal scale-up. J Pharm Sci 98:4327–4342.
   PubMed Web of Science ®Google Scholar
• Kannel WB, Castelli WP, Gordon T, McNamara PM. (1971). Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med 74:1–12.
   PubMed Web of Science ®Google Scholar
• Kim MS, Wang S, Shen Z, Kochansky CJ, Strauss JR, Franklin RB, Vincent SH. (2004). Differences in the pharmacokinetics of peroxisome proliferator-activated receptor agonists in genetically obese Zucker and sprague-dawley rats: implications of decreased glucuronidation in obese Zucker rats. Drug Metab Dispos 32:909–914.
   PubMed Web of Science ®Google Scholar
• Kobuchi S, Fukushima K, Shibata M, Ito Y, Sugioka N, Takada K. (2011). Pharmacokinetics of clomipramine, an antidepressant, in poloxamer 407-induced hyperlipidaemic model rats. J Pharm Pharmacol 63:515–523.
   PubMed Web of Science ®Google Scholar
• Kroemer HK, Gautier JC, Beaune P, Henderson C, Wolf CR, Eichelbaum M. (1993). Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol 348:332–337.
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee MG. (2008). Telithromycin pharmacokinetics in rat model of diabetes mellitus induced by alloxan or streptozotocin. Pharm Res 25:1915–1924.
   PubMed Web of Science ®Google Scholar
• Lee JH, Oh JH, Lee YJ. (2011a). Effects of experimental hyperlipidaemia on the pharmacokinetics of docetaxel in rats. Xenobiotica 41:797–804.
   PubMed Web of Science ®Google Scholar
• Lee YS, Kim YW, Kim SG, Lee I, Lee MG, Kang HE. (2011b). Effects of poloxamer 407-induced hyperlipidemia on the pharmacokinetics of carbamazepine and its 10,11-epoxide metabolite in rats: Impact of decreased expression of both CYP3A1/2 and microsomal epoxide hydrolase. Eur Neuropsychopharmacol. DOI: http://dx.doi.org/10.1016/j.euroneuro.2011.10.004
   Google Scholar
• Leon C, Wasan KM, Sachs-Barrable K, Johnston TP. (2006). Acute P-407 administration to mice causes hypercholesterolemia by inducing cholesterolgenesis and down-regulating low-density lipoprotein receptor expression. Pharm Res 23:1597–1607.
   PubMed Web of Science ®Google Scholar
• Levy RH, Thummel KE, Trayer WF, Hansten PD, Eichelbaum M eds (2000). Metabolic drug interactions. Philadelphia, PA: Lippincott Williams & Wilkins, 341.
   Google Scholar
• Lineweaver H, Burk D. (1934). The determination of enzyme dissociation constants. J Am Chem Soc 56:658–666.
   Web of Science ®Google Scholar
• Manitpisitkul P, Chiou WL. (1993). Intravenous verapamil kinetics in rats: marked arteriovenous concentration difference and comparison with humans. Biopharm Drug Dispos 14:555–566.
   PubMedGoogle Scholar
• Øie S, Guentert TW. (1982). Comparison of equilibrium time in dialysis experiments using spiked plasma or spiked buffer. J Pharm Sci 71:127–128.
   PubMed Web of Science ®Google Scholar
• Palmer WK, Emeson EE, Johnston TP. (1997). The poloxamer 407-induced hyperlipidemic atherogenic animal model. Med Sci Sports Exerc 29:1416–1421.
   PubMed Web of Science ®Google Scholar
• Patel JP, Brocks DR. (2009). The effect of oral lipids and circulating lipoproteins on the metabolism of drugs. Expert Opin Drug Metab Toxicol 5:1385–1398.
   PubMed Web of Science ®Google Scholar
• Shayeganpour A, Jun AS, Brocks DR. (2005). Pharmacokinetics of Amiodarone in hyperlipidemic and simulated high fat-meal rat models. Biopharm Drug Dispos 26:249–257.
   PubMed Web of Science ®Google Scholar
• Shayeganpour A, Korashy H, Patel JP, El-Kadi AO, Brocks DR. (2008). The impact of experimental hyperlipidemia on the distribution and metabolism of amiodarone in rat. Int J Pharm 361:78–86.
   PubMed Web of Science ®Google Scholar
• Sugioka N, Haraya K, Maeda Y, Fukushima K, Takada K. (2009). Pharmacokinetics of human immunodeficiency virus protease inhibitor, nelfinavir, in poloxamer 407-induced hyperlipidemic model rats. Biol Pharm Bull 32:269–275.
   PubMed Web of Science ®Google Scholar
• Sun CK, Zhang XY, Wheatley AM. (2003). Increased NAD(P)H fluorescence with decreased blood flow in the steatotic liver of the obese Zucker rat. Microvasc Res 66:15–21.
   PubMedGoogle Scholar
• Tracy TS, Korzekwa KR, Gonzalez FJ, Wainer IW. (1999). Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil. Br J Clin Pharmacol 47:545–552.
   PubMed Web of Science ®Google Scholar
• Vaidya H, Rajani M, Sudarsanam V, Padh H, Goyal R. (2009). Antihyperlipidaemic activity of swertiamarin, a secoiridoid glycoside in poloxamer-407-induced hyperlipidaemic rats. J Nat Med 63:437–442.
   PubMed Web of Science ®Google Scholar
• Varma MV, Panchagnula R. (2005). Prediction of in vivo intestinal absorption enhancement on P-glycoprotein inhibition, from rat in situ permeability. J Pharm Sci 94:1694–1704.
   PubMed Web of Science ®Google Scholar
• Vogelgesang B, Echizen H, Schmidt E, Eichelbaum M. (1984). Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique. Br J Clin Pharmacol 18:733–740.
   PubMed Web of Science ®Google Scholar
• Wilkinson GR, Shand DG. (1975). Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18:377–390.
   PubMed Web of Science ®Google Scholar
• Yoon NY, Kim HR, Chung HY, Choi JS. (2008). Anti-hyperlipidemic effect of an edible brown algae, Ecklonia stolonifera, and its constituents on poloxamer 407-induced hyperlipidemic and cholesterol-fed rats. Arch Pharm Res 31:1564–1571.
   PubMed Web of Science ®Google Scholar
• Yoshinari K, Takagi S, Yoshimasa T, Sugatani J, Miwa M. (2006). Hepatic CYP3A expression is attenuated in obese mice fed a high-fat diet. Pharm Res 23:1188–1200.
   PubMed Web of Science ®Google Scholar